Euroapi S.A. (EPA:EAPI)
France
· Delayed Price · Currency is EUR | Market Cap | 123.74M |
| Revenue (ttm) | 852.60M |
| Net Income (ttm) | -211.20M |
| Shares Out | 95.19M |
| EPS (ttm) | -2.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346,706 |
| Average Volume | 142,770 |
| Open | 1.310 |
| Previous Close | 1.300 |
| Day's Range | 1.274 - 1.422 |
| 52-Week Range | 1.220 - 3.572 |
| Beta | 0.95 |
| RSI | 49.84 |
| Earnings Date | Jul 28, 2026 |
About Euroapi
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances.... [Read more]
Full Company ProfileFinancial Performance
In 2025, Euroapi's revenue was 852.60 million, a decrease of -7.25% compared to the previous year's 919.20 million. Losses were -211.20 million, 61.7% more than in 2024.
Financial StatementsNews
EUROAPI - Availability of the 2025 Universal Registration Document
Press Release Availability of the 2025 Universal Registration Document, including the Annual Financial Report Paris – March 27, 2026 – EUROAPI announces the publication of its 2025 Universal Reg...
Euroapi Earnings Call Transcript: H2 2025
Net sales declined 7% to EUR 848 million in 2025, with core EBITDA up 31% to EUR 66.2 million and a margin of 7.8%. Portfolio rationalization and cost discipline drove improved profitability, but a 10% sales decrease is expected in 2026 amid ongoing market pressures.
Abolis Biotechnologies and EUROAPI Enter Into Partnership to Accelerate Pharmaceutical Innovation and Restore European Sovereignty
ÉVRY-COURCOURONNES, France--(BUSINESS WIRE)--Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, today announced that it has entered into a strategic partnersh...
With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty
The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in Europe
Science Based Targets initiative (SBTi) validates EUROAPI's near-term climate targets
September 18, 2025 - EUROAPI's near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company's alignment with the Paris ...
Euroapi Earnings Call Transcript: H1 2025
Net sales declined 8.2% year-over-year to EUR 412 million, with core EBITDA margin at 9.6% and a net loss of EUR 28.5 million. H2 is expected to strengthen, driven by HP API sales, CMO activity, and vitamin B12 recovery, while cost discipline and strategic investments continue.
EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan
Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with ...
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce th...
Euroapi Transcript: AGM 2025
The AGM reviewed a challenging 2024 marked by lower revenues, a net loss, and major restructuring under the Focus 27 plan. All resolutions were approved, including governance and compensation changes, with management emphasizing restored profitability, diversification, and ESG progress.
Euroapi Earnings Call Transcript: H2 2024
Net sales fell 10% to EUR 911.9 million in 2024, with core EBITDA margin at 5.5% and a net loss of EUR 130.6 million. Focus 27 plan advanced, with 2025 guidance for steady sales and improved 7-9% EBITDA margin, supported by ongoing cost and portfolio optimization.
EUROAPI moves into a new chapter with new Governance and Leadership
Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company's Board of Directors has accepted today the res...
Olivier Falut appointed EUROAPI's Chief Financial Officer
Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI's Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evely...
EUROAPI closes the financing of its FOCUS-27 plan
Paris - 15 October 2024 - EUROAPI today announces the closing of the refinanced Credit Revolving Facility (RCF) and the Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi, thus completing ...
EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution
“The completion of the financing is an instrumental step in the execution of EUROAPI's strategic roadmap” said Ludwig de Mot, Chief Executive Officer. “ Combined with further developments in our comme...
Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi
SAN FRANCISCO--(BUSINESS WIRE)-- #gxp--Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon E...
EUROAPI - Availability of 2024 Half-Year Financial Report
Paris, 05 August, 2024 – EUROAPI posted today its 2024 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2024. This document is available for consultation and dow...
Euroapi Earnings Call Transcript: H1 2024
H1 2024 saw a 9.6% drop in net sales and a 23.8% decline in core EBITDA, mainly due to lower Sanofi volumes and Brindisi suspension, but gross margin improved. FOCUS-27 transformation is progressing, with restructuring and financing on track, and full-year guidance confirmed despite ongoing challenges.
Euroapi Transcript: Investor Update
FOCUS-27 will transform operations by discontinuing loss-making APIs, divesting two sites, and focusing on profitable products and CDMO growth. 2024 guidance anticipates lower sales and EBITDA, with significant restructuring and capital investments planned.
EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1
Press Release Agreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving Credit...
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
Paris – June 18, 2024 – EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules for the treatme...
EUROAPI reaches major Health IPCEI milestone with official notification from European Commission
Paris – June 6, 2024 – EUROAPI has received official notification from the European Commission that the Company has been selected as one of the 13 companies eligible to share up to EUR 1 billion in to...
EUROAPI strengthens its presence in animal health with a €130-150 million supply contract
Paris – May 23, 2024 – EUROAPI announces today that it has entered into a Contract Manufacturing Organization (CMO) agreement with a global animal health company. As part of this collaboration, EUROAP...
Evelyne Nguyen appointed EUROAPI's Chief Financial Officer
Paris – May 13, 2024 - Evelyne Nguyen has been appointed EUROAPI's Chief Financial Officer, effective May 14, 2024, and will be a member of the Executive Committee. She is taking over from Antoine Del...
EUROAPI streamlines its Executive Committee to improve focus and efficiency
Paris – April 9, 2024 – EUROAPI today announces a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. This organizational adjustment is part ...